Li Q - Search Results

1

Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE. Li Q, et al. Cancer Res. 2005 Feb 1;65(3):1063-70. Cancer Res. 2005. PMID: 15705908

2

Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.

Li Q, Yu B, Grover AC, Zeng X, Chang AE. Li Q, et al. J Immunother. 2002 Jul-Aug;25(4):304-13. doi: 10.1097/00002371-200207000-00002. J Immunother. 2002. PMID: 12142553

3

Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.

Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE. Li Q, et al. Cancer Res. 2003 May 15;63(10):2546-52. Cancer Res. 2003. PMID: 12750278

4

Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.

Ito F, Carr A, Svensson H, Yu J, Chang AE, Li Q. Ito F, et al. Among authors: li q. J Immunother. 2003 May-Jun;26(3):222-33. doi: 10.1097/00002371-200305000-00006. J Immunother. 2003. PMID: 12806276

5

Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration.

Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE. Teitz-Tennenbaum S, et al. Among authors: li q. Cancer Res. 2003 Dec 1;63(23):8466-75. Cancer Res. 2003. PMID: 14679011

6

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.

Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, Chang AE. Ito F, et al. Among authors: li q. Cancer Res. 2004 Nov 15;64(22):8411-9. doi: 10.1158/0008-5472.CAN-04-0590. Cancer Res. 2004. PMID: 15548712

7

Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE. Li Q, et al. J Immunol. 2005 Aug 1;175(3):1424-32. doi: 10.4049/jimmunol.175.3.1424. J Immunol. 2005. PMID: 16034078

8

Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.

Macgregor JN, Li Q, Chang AE, Braun TM, Hughes DP, McDonagh KT. Macgregor JN, et al. Among authors: li q. Cancer Res. 2006 May 1;66(9):4913-21. doi: 10.1158/0008-5472.CAN-05-3507. Cancer Res. 2006. PMID: 16651448

9

Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Iuchi T, Teitz-Tennenbaum S, Huang J, Redman BG, Hughes SD, Li M, Jiang G, Chang AE, Li Q. Iuchi T, et al. Among authors: li m, li q. Cancer Res. 2008 Jun 1;68(11):4431-41. doi: 10.1158/0008-5472.CAN-07-5530. Cancer Res. 2008. PMID: 18519706 Free PMC article.

10

In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. Li Q, et al. Among authors: li m. J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10. J Immunol. 2009. PMID: 19667089 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65,845 results

Search Page

Filters